Proteins and Peptides
9 December 2014
Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting8 December 2014
Lipella’s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial8 December 2014
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®8 December 2014
Novoeight® Phase 3 Data Show Reduction in Annualised Bleeding Rate Over Time in People With Haemophilia A8 December 2014
BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference5 December 2014
Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program2 December 2014
Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection2 December 2014
Preclinical Data Published on AM-Pharma’s recAP to Treat Ultra Rare Disease Hypophosphatasia1 December 2014
Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A28 November 2014
Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in Adult Patients25 November 2014
Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model24 November 2014
Novartis drug Signifor® approved in EU, marking an advance for patients with inadequately controlled acromegaly21 November 2014
Victoza(R) receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal impairment21 November 2014
Proteo, Inc. / Proteo Biotech AG: Final Analysis of the Phase II Clinical Study on Elafin in Coronary Artery Bypass Surgery Completed18 November 2014
CKD Pharmaceuticals achieves tolerated well, and showed a comparable PK, PD, and tolerability profile to that of NESP® (Darbepoetin alfa).17 November 2014
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes17 November 2014
Allena Pharmaceuticals Presents Phase 1 Data on ALLN-177 at American Society of Nephrology Kidney Week 2014News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports